Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Fundamental Fields and Compact Objects: new opportunities (NewFunFiCO)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Staff Exchanges
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Portugal,Spain,China,Germany,Mexico,Brazil
Call: MSCA Staff Exchanges 2021 (HORIZON-MSCA-2021-SE-01, 2021)
Start date: 2023-01-01
End date: 2026-12-31
Duration (months): 48.0
Total project cost (EUR): 276000.0
EU funding (EUR): 276000.0
Participants: 6
Project status: SIGNED

The celebrated detection of gravitational waves (GWs), the first observation of horizon scale structure of a black hole (BH) together with the developments in the field of numerical relativity, are allowing access to extreme (strong and dynamical) gravity configurations, both observationally and theoretically, making our time a golden epoch for studying extreme gravitational systems. In parallel, families of exotic but theoretically sound models of BHs and horizonless compact objects in the presence of new fundamental fields, or alternative theories of gravity have been constructed, to a large extent numerically. These can be submitted to computational experiments, to test their dynamics, and compared against observations, to address the issue of degeneracy in the theoretical interpretations of strong gravity data or even detect putative better fits to the data. At the meeting point between these two developments lies the promise of new fundamental physics, a deeper understanding of BHs and neutron stars, unveling the nature of dark matter and dark energy. Delivering on this promise requires a synergetic endeavour that must bring together different groups and competences. This project creates a multi-connected team with different and complementary scientific expertises - on BHs, neutron stars and exotic compact objects -, their phenomenology - GWs, lensing and astrophysical environments - and the techniques necessary to extract the latter from the former for comparison with observations, including constructing and evolving solutions of non-standard compact objects with numerical methods, building GW libraries, lensing images and performing data/Bayesian analysis and parameter estimation. The team includes members of the LIGO-Virgo-Kagra and Event Horizon Telescope collaborations, providing a direct connection to observations, and will explore deep learning frameworks to face the key challanges of model classification and data augmentation.

Keywords: black holes,gravitational waves,numerical solutions,numerical relativity,deep learning
Hybrid Nanocomposite Scintillators for Transformational Breakthroughs in Radiation Detection and Neutrino Research (UNICORN)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Italy,France,Czechia,Spain,Switzerland
Call: EIC Pathfinder Open 2022 (HORIZON-EIC-2022-PATHFINDEROPEN-01, 2022)
Start date: 2023-06-01
End date: 2027-05-31
Duration (months): 48.0
Total project cost (EUR): 2995000.0
EU funding (EUR): 2995000.0
Participants: 8
Project status: SIGNED

The goal of UNICORN is to develop unprecedented nanocomposite scintillator (SL) detectors based on engineered nanomaterials for transformative breakthroughs in strategic radiation detection areas spanning homeland security and medicine to industrial, nuclear, and environmental monitoring to cosmology and high energy/particle physics. Today, conventional inorganic SL crystals are prohibitively energy-intensive, fragile, heavy and cannot be produced in large quantities. Organic SLs are, in turn, affordable and scalable, but their low density and light yield reduce energy resolution. These shortcomings preclude progress in application areas of great importance and impose a technological bottleneck to the fundamental study of rare events. The most at risk of all is the study of neutrinoless Double Beta Decay (0νDBD), a so far undetected, rare nuclear process that represents the Holy Grail in particle physics, whose observation would provide long sought-after answers on the origin of the Universe and unlock unexplored scientific territories with unimaginable progress perspectives. UNICORN will tackle this urgent grand challenge by introducing revolutionary nanotechnology-based concepts combining high energy resolution, efficiency, and stability with unmatched mass scalability. The keystone of our disruptive approach are inorganic nanocrystals (NCs) that will be specifically designed to be both the source of 0νDBD and high-performance nano-SLs. The breakthrough will also consist in achieving perfect compatibility with (in)organic hosts to obtain unparalleled ultra-high density optical-grade nanocomposite detectors with maximized light output to be coupled to custom-made light sensors that will embody the archetype of advanced radiation detectors of the future. UNICORN combines world-leading institutions and companies with complementary interdisciplinary competences ensuring the pivotal synergy to reach the project goals and rapidly translate results into economic value.

Keywords: scintillators,nanocrystal quantum dots,polymer nanocomposites,glass nanocomposites,radiation detection,neutrinoless double beta decay
Preclinical development of a 3rd-generation interleukin-2 targeted to inflammatory sites (TiilT)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Tackling diseases and reducing disease burden
Action type: Research and Innovation actions
Countries involved: France,Austria,Italy,Estonia,United Kingdom,Germany
Call: Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs (HORIZON-HLTH-2022-DISEASE-06-two-stage, 2022)
Start date: 2023-06-01
End date: 2028-05-31
Duration (months): 60.0
Total project cost (EUR): 5605576.25
EU funding (EUR): 5605576.25
Participants: 10
Project status: SIGNED

As major players in the regulation of immune responses, regulatory T cells (Tregs) are important therapeutic targets for autoimmune and inflammatory diseases. Interleukin-2 (IL-2) used at low doses (IL-2LD) stimulate and expand Tregs in vivo. While 1st-generation native IL-2LD are currently under extensive clinical evaluation, pharmaceutical companies are developing 2nd-generation IL-2 muteins with improved half-life and activity. We aim to develop 3rd-generation IL-2 specifically targeting inflammatory sites (IL-2IT) by using antibodies (Abs) against oxidation specific epitopes (OSE) that are both universal markers and mediators of inflammation. IL-2-OSE-Ab fusion proteins should allow dampening of local inflammation by a double-hit mechanism involving Ab neutralization of pro-inflammatory OSE and IL-2 stimulation of Tregs. As a proof of concept, we designed a first IL-2IT in which an IL-2N88R mutein is fused to an scFv from a prototypic anti-OSE Ab. This IL-2IT (i) binds to IL-2 receptors and OSE, (ii) has an extended half-life and (iii) superior therapeutic efficacy compared to native IL-2 in mice. Our general objectives are to design an optimized IL-2IT by testing combinations of different anti-OSE Ab with IL-2 and IL-2 muteins, and to complete its preclinical development in mice and macaques. We will validate the use of IL-2IT in cardiovascular diseases (CVD), i.e. atherosclerosis, vasculitis, myocardial infarction and SLE-associated CVD, as these conditions have been shown to be improved by Treg infusions, native IL-2 and OSE-Abs in mice. Carried by leading experts in the use IL-2, OSE-Abs, models of CVD, and clinical trials with native IL-2, the successful validation of an IL-2IT will open a new era for highly selective and effective immunotherapies based on Treg stimulation for diseases that represent a leading cause of death and morbidity. Furthermore, it will validate the broader concept of targeting any therapeutic molecule to inflammatory sites.

Keywords: interleukin 2,regulatory t cells,oxidation specific epitopes,inflammation,cardiovascular diseases,atherosclerosis,myocardial infarction,autoimmune diseases,inflammatory diseases,sle
Halide solid state batteries for ELectric vEhicles aNd Aircrafts (HELENA)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Energy
Destination: Cross-sectoral solutions for the climate transition
Action type: Research and Innovation actions
Partnership: Batteries (co-programmed)
Countries involved: Spain,Austria,France,Belgium,Netherlands,Germany,Slovenia,Italy
Call: Advanced high-performance Generation 4a, 4b (solid-state) Li-ion batteries supporting electro mobility and other applications (Batteries Partnership) (HORIZON-CL5-2021-D2-01, 2021)
Start date: 2022-06-01
End date: 2026-05-31
Duration (months): 48.0
Total project cost (EUR): 8366963.5
EU funding (EUR): 8366963.5
Participants: 18
Project status: SIGNED

To support the upcoming short-term needs of the battery industry, it is imperative to have new differentiating European battery technology for 4b generation batteries on the market from 2025. Halide solid state batteries for ELectric vEhicles aNd Aircrafts (HELENA) responds to the need of the development of a safe, novel high energy efficiency and power density solid state battery (4b generation batteries) cells, based on high capacity Ni-rich cathode (NMC), high-energy Li metal (LiM) anode and Li-ion superionic halide solid electrolyte for application in electric vehicles and, especially in aircrafts. HELENA will support Europe, in this sense, on its transition towards a climate-neutral continent since electric aviation is poised to take off within the next five to 10 years, with innovations already being pursued for electric vehicle batteries. Moreover, HELENA will avoid dependence on Asia for battery production. HELENA is built by a multidisciplinary and highly research experienced consortium that covers the whole battery value chain and proposes a disruptive halide-based solid-state cell technology with the overall aim to significantly increase the adoption of these batteries on aircrafts and EVs The technical challenges that are presented by current conventional battery technology and the consumer needs will be overcome - especially the reduction in costs of battery devices, enable scalable and safe cell manufacturing, increasing their capabilities for long distance traveling and fast charging, ensuring a high safety of the battery.

Keywords: solid state battery,halide electrolyte,high voltage cathodes,li metal anode,battery testing,battery aging,battery modelling,recycling,life cycle analysis,life cycle costing,aircraft,ev
Uncovering commonalities and differences: Towards a novel framework for identifying end-of-life trajectories of older people with serious chronic illness (TRAJECT)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Human Mobility, Environment, and Space
Panel description: Human geography, demography, health, susta inability science, territorial planning, spatial analysis
Countries involved: Belgium
Call: ERC STARTING GRANTS (ERC-2022-STG, 2022)
Start date: 2023-10-01
End date: 2028-09-30
Duration (months): 60.0
Total project cost (EUR): 1440500.0
EU funding (EUR): 1440500.0
Participants: 1
Project status: SIGNED

Older people who die from serious chronic disease typically experience long periods (months or years) of illness and complex fluctuations in their physical health and in their social, psychological, and existential well-being. This project will conduct a mixed-method, inter-disciplinary investigation of these end-of-life trajectories. It responds to the long-standing scientific challenge of identifying commonalities in end-of-life trajectories across groups of people, without masking important inter-individual differences. Its central aim is to gain understanding of what is generalisable and what is individually specific in older people’s end-of-life trajectories and in the circumstances that shape them. This project applies a novel methodological and analytical framework, examining trajectories through two distinct scientific lenses: a structured quantitative approach known from the biomedical sciences to capture fluctuations in a standardised way, and an experience-focused qualitative approach from the humanities to study the subjective stories and meanings behind changes in health. In a convergent mixed-methods investigation, this work combines 1) a large quantitative longitudinal study and 2) a serial narrative interview study; both with older people (70 years or over) with serious chronic illness who are nearing the end of life. The results of these two methods will be integrated through triangulation and by systematically threading key findings from one method across to the other. This work will lead to a fundamental re-thinking of how we examine, understand, and categorise end-of-life trajectories. It will reveal the full extent of their complexity and indicate possibilities and limits of generalisation. These novel insights will propel scientific advances towards achieving a good end of life in ageing societies. They will also drive methodological innovation beyond my field, balancing the perspective of the researcher and the researched.

Keywords: end of life trajectories,older people,longitudinal research,mixed methods research,narrative research
Piloting Innovative Insurance Solutions for Adaptation (PIISA)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Mission
Theme: Adaptation to climate change
Destination: Adaptation to climate change
Action type: Research and Innovation actions
Countries involved: Finland,Spain,Italy,France,Netherlands
Call: Best practices on and piloting insurance solutions for climate adaptation in EU regions and communities (HORIZON-MISS-2022-CLIMA-01, 2022)
Start date: 2023-06-01
End date: 2026-05-31
Duration (months): 36.0
Total project cost (EUR): 2918968.75
EU funding (EUR): 2918968.75
Participants: 12
Project status: SIGNED

The EU Member States should step up their climate change adaptation efforts alongside their intensifying mitigation efforts. Next to and in conjunction with physical and organizational measures, that directly reduce climate change risks, insurance and related risk sharing solutions have an important role to play. Innovative insurance solutions and risk sharing are crucially needed to incentivize adaptation efforts, in terms of both volume and effectiveness, while also directly contributing to building more resilient societies. The PIISA project aims to develop and deploy a range of insurance innovations that incite households and firms to adapt proactively and sufficiently for their own sake and their neighborhood’s sake. PIISA also incites public authorities to set up adaptation and create adaptation promoting conditions. PIISA co-develops climate resilient insurance portfolios and develops solutions for sharing losses and climate risk data. The PIISA project matches scientifically underpinned new insurance concepts with hands-on demonstration of their operability, effectiveness, and acceptability. Extensive user involvement, contextual sensitization, affordability and viability are key features of the new products. The choice of new product developments and sectoral applications will be based on a careful analysis of the adaptation and insurances gaps and their interactions, as well as on deepening product-market feasibility analyses. PIISA focal sectors are agriculture, forest sector, and cities and citizens’ well-being, involving a host of climate enhanced hazards such as floods, droughts, forest fires, biotic risks, and various types of storms. The consortium counts 12 partners from 5 countries. PIISA involves 3 insurance companies who will actively participate in the insurance pilots conducted in 8 countries, also using their vast multi-million customer base.

Keywords: food and agriculture,carbon insurance
Cooperative business models for bio-based chains in rural areas (BRILIAN)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Public-private partnerships
Destination: Circular Bio-based Europe
Action type: Innovation actions
Partnership: CBE (JU-JTI)
Countries involved: Spain,Italy,Denmark,Greece,Belgium,Czechia
Call: Cooperative business models for the sustainable mobilisation and valorisation of agricultural residues, by-products, and waste in rural areas (HORIZON-JU-CBE-2022, 2022)
Start date: 2023-06-01
End date: 2027-05-31
Duration (months): 48.0
Total project cost (EUR): 6167721.25
EU funding (EUR): 4886349.75
Participants: 13
Project status: SIGNED

Aiming at increasing farmers’ income and to be fully aligned with the Common Agricultural Policy (CAP) while addressing also Green Deal and Bioeconomy Strategy objectives, BRILIAN will support the adoption of sustainable cooperative business models in rural areas. These business models will enhance rural development, biodiversity preservation and climate-neutrality. For that, BRILIAN will implement a multi-actor approach for the validation of a group of Actions for the Bio Innovation (ABI) both at macro and micro level. The Actions for the Bio-Innovation are ABI 1. Forging robust rural bio-communities. ABI 2. Achieving circularity and sustainability. ABI 3. Integration of short supply chains and ABI 4. Production of value-added bioproducts. Therefore, BRILIAN innovations will allow primary producers to diversify their incomes while reducing risks. These ABI will be particularized for 3 pilots in Italy, Spain and Denmark. Within these pilots, a set of business models will be enhanced and tested for the validation of 10 value chains. 6 in Italy, 2 in Spain and 2 in Denmark. BRILIAN pilots will make use of existing rural infrastructures but implementing adaptations to the current main processes and contractual agreements between actors. To strength that, business model design aproaches will be supported by modules dealing with logistic, organizational and sustainability factors weighted in the BRILIAN optimization toolkit, a toolkit based on complex models which will provide support for the design and optimization of biobased value chains, putting primary producers in the centre. As a result, BRILIAN will set long-term strategies for the adoption of cooperative business models in EU, facilitated by the generation of 11 key exploitable results during the project, including Technical, Socioeconomic, Policy & regulation and Academic ones. The implementation of such an ambitious project requires of a consortium of 13 partners with 11 BIC members.

Keywords: bioeconomy business model primary producers farmers cooperatives feedstock soil rural biobased water management logistics organisational sustainability investments bioproducts training
Next Generation Glioma Treatments using Direct Light Therapy (GlioLighT)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Germany,Spain,Finland,United Kingdom,Serbia
Call: EIC Pathfinder Open (HORIZON-EIC-2023-PATHFINDEROPEN-01, 2023)
Start date: 2024-01-01
End date: 2026-12-31
Duration (months): 36.0
Total project cost (EUR): 2804298.3
EU funding (EUR): 2804298.3
Participants: 8
Project status: SIGNED

Glioma is an extremely lethal cancer, due largely to the inaccessible nature of the brain and diffusion of cells from the tumour site. These diffuse cells are usually too deeply embedded in the brain to safely remove by current means. Targeted Reactive Oxygen Species (ROS) generation is a promising form of glioma treatment to selectively eliminate glioma, including diffuse cells. However, the only current means of targeted ROS generation is photodynamic therapy (PDT) which generates ROS using expensive and potentially toxic photosensitisers (PS) which are ineffective against distant diffused cells and introduce many treatment limitations. GlioLighT proposes a novel alternative form of targeted ROS generation: Direct Light Therapy (DLT). DLT uses 1267nm light to generate 1O2 species in glioma cells without dependency on a PS. The removal of PS will revolutionise glioma treatment, enabling novel treatment modalities to vastly improve efficacy, earlier intervention options, all at reduced cost and complexity. However, whilst the principles of DLT have been demonstrated, little is known about how DLT achieves its anti-cancer effects, or the extent of its therapeutic benefits. Leveraging decades of accumulated PDT knowledge and technology development, GlioLighT will study DLT technology both independently and compared to PDT. The effect of DLT on glioma and the brain, focusing on immunogenicity, will be studied to determine DLT’s efficacy, safety, and mechanisms of action. Novel ultrashort pulse (USP) light sources will be developed to maximise optical penetration and minimise safety risk, ensuring DLT is suited for clinical adoption. Lastly, the development of the preclinical GlioLighT delivery and sensing system (pcGlio-DSS) ready for the next steps of clinical translation, will bring DLT a leap closer to vastly improving glioma treatment in Europe and worldwide.

Keywords: immuno oncology,reactive oxygen species,neurobiology,metabolism,photonics,photodynamic therapy